Meril Life - The First Company In The World To Launch A Drug Eluting Stent With The World's Thinnest Struts
As a medical device manufacturer, we at Meril Life believe in delivering world-class health solutions with the latest and most effective medical equipment, created in our ultra-modern manufacturing facilities. As global innovators and trendsetters, we strive to identify unmet clinical needs and produce relevant devices with quick turnaround cycles. Our dedicated research and development team empowers us to create products and therapy methods that truly focus on alleviating human suffering and improving quality of life.
Coronary artery diseases, caused by a buildup of plaque in our arteries are the world’s leading cause of death. Plaque buildup, if left unchecked can cause heart arrhythmia, cardiac arrest, heart failure and even death. The new Evermine50™, a drug-eluting coronary stent system by Meril Life, gives patients a non-surgical procedure that results in improvement in heart functions without the need for pacemakers.
What is the Evermine50™?
The Biodegradable polymer, Evermine50™ is an everolimus-eluting coronary stent system made with an ultrathin (50 μm) strut stent design. The use of catheters to deal with heart issues has been around for a while. Surgeons would implant
bare-metal stents inside arteries to hold the artery open and improve blood flow to the heart. This proved to be an ineffective solution as these stents would require re-narrowing or restenosis every 6-12 months in 1 out of 3 patients. To combat this, Meril Life Sciences came up with a biocompatible and biodegradable polymer, which is a drug-eluting stent with the thinnest struts in the world. This stent does not cause restenosis and releases a drug to prevent blockage and keeps your arteries clear for a longer period of time.
What sets us apart?
The Evermine50™ has a unique hybrid honey-comb cell design made from the Co-Cr L605 alloy. Its unique design gives it outstanding radial strength and visibility, while still focusing on flexibility and deliverability. The ultra-low strut thickness of just 50 µm minimises chances of vascular injury without compromising radial strength. The catheter has been designed specially with short balloon shoulders and a low balloon overhang to minimise balloon related edge injury. The stent uses a low tip entry profile and is delivered through a highly flexible system making it a healthcare solution that deals with coronary complications with minimal risk.
We at Meril Life have our patients’ long-term safety and health as our highest priority. Compared to stents with thicker struts in the market, the Evermine50™ leads to lesser vessel injury, lowered risk of inflammation and reduced chances of thrombus formation. Clinical studies show that the Evermine50™ helps patients to avoid pacemaker implantation for up to 12 months post-procedure. With a minimally invasive procedure that leads to a shorter hospital stay and quicker recovery rates, this is a stent that puts the patient first in every manner.
Meril Life Sciences is committed to alleviate human suffering and improve the quality of life by manufacturing and delivering path-breaking medical devices and healthcare products. Our innovation, design and development all prioritise, minimising risks for patients. The Evermine50™ is just one of the many ways in which we as a medical device manufacturer hope to improve the inventiveness in healthcare and enrich people’s lives.